Trials / Withdrawn
WithdrawnNCT00512863
A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel, Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 272 (estimated)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of SC injections of 3 regimens of adalimumab vs. placebo in the change in post-bronchodilator FEV1 from Baseline to Week 16 when used in the treatment of refractory asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Humira (adalimumab) |
Timeline
- Start date
- 2007-08-01
- First posted
- 2007-08-08
- Last updated
- 2007-11-06
Source: ClinicalTrials.gov record NCT00512863. Inclusion in this directory is not an endorsement.